Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087235 | 1.00 | TNF (0.37) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL28584478 | 0.82 | HTR2A (0.41) | HTR2AHTR2CHTR2BLMNACYP2A6 | |
| SCHEMBL9847889 | 0.82 | TNF (0.46) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL1003501 | 0.81 | TNF (0.35) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL29414007 | 0.81 | TNF (0.35) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL29071566 | 0.81 | HTR2A (0.32) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL9339526 | 0.81 | HTR2A (0.32) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL25263788 | 0.77 | TNF (0.33) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL22289306 | 0.77 | NPC1 (0.32) | HTR2AHTR2CHTR2BNPC1RAB9A | |
| SCHEMBL20595059 | 0.77 | PTGER4 (0.41) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-3992176-B1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO (JP) | 2025-08-27 | — | — | EP | disclosed |
| CN-119390685-A | Polysubstituted carbazole-containing organic compound and organic electroluminescent device thereof | 广州启星光电科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119173505-A | Antiviral heterocyclic compounds | 英安塔制药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-116925111-A | Organic compound and application thereof | 北京鼎材科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20220388955-A1 | EP2 ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | US | disclosed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022138793-A1 | COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| EP-3992176-A1 | EP2 ANTAGONIST | ONO Pharmaceutical Co., Ltd. (JP) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388955-A1 | EP2 ANTAGONIST | PTGER2, PTGER1, PTGES2 | TNF 2500/4885RIPK1 3063/4885HTR2A 66/4885 |
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | TNF 4032/4885RIPK1 3428/4885HTR2A 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.